Archive for October 2018
SUPPORT for Patients and Communities Act
SUPPORT for Patients and Communities Act President Donald Trump signed the bi-partisan opioid legislation on October 24. According to Vox, the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act “is a big breakthrough that will boost access to addiction treatment and many other interventions to mitigate the…
Read MorePersonalized Pain Medicine
Below is an edited excerpt from a chapter titled, Pharmacogenetics and Personalized Medicine in Pain Management, that Inna Belfer, MD PhD and I published in Clinics in Laboratory Medicine, Volume 36, Issue 3, September 2016. Personalized Pain Medicine Pharmacogenetic therapy in people with pain requires consideration of 2 different genetic substrates to determine the outcome…
Read MoreMy Testimony Before the ADCOM for AcelRex’s DSUVIA
On Friday, Oct. 12, 2018, AcelRex Pharmaceuticals, Inc. presented its case to the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (ADCOM) to discuss the approval of the new drug application (NDA) 209128 for DSUVIA™. DSUVIA is a small sufentanil pill deposited below the tongue with an applicator. It is…
Read MoreHealth Professionals Call on the CDC to Address Misapplication of Its Guideline
Stefan G. Kertesz, MD Pens a Letter to the CDC Health Professionals Call on the CDC to Address Misapplication of Its Guideline on Opioids for Chronic Pain through Public Clarification and Impact Evaluation by Health Professionals for People in Pain is a letter that I recently had the privilege of signing. (Click here to see…
Read More